NEA MANAGEMENT COMPANY LLC
Q2 2025 Form 13-F
TIMONIUM, MARYLAND
CIK 0001512848
· CRD 161004
· SEC-registered investment adviser
$1.3B Reported Value Total
NEW ENTERPRISE ASSOCIATES reports 21 total accounts under management (AUM). There are 21 discretionary accounts valued at $27,827,259,258, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
30 funds
· $35.6B gross asset value
Venture Capital Fund: $34.6B · Private Equity Fund: $1.0B
Source: Form ADV filed 2026-08-26
Reported value
$1.3B
Quarter over quarter
+14.9%
Holdings
32
Top-10 concentration
81.3%
Key People
Form ADV owners & control persons
Anthony Angelo Florence
MEMBER OF THE MANAGING MEMBER OF THE ADVISER
Stephanie Siegal Brecher
CHIEF LEGAL OFFICER
Sam D Cohen
CHIEF FINANCIAL OFFICER, CORPORATE FINANCE AND TAX
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2025 13F record
Q2 2025 13F filing summary
| Period of report | June 30, 2025 |
|---|---|
| Filed | August 14, 2025 |
| Form | 13F-HR |
| Reported value | $1.3B |
| Positions | 32 |
| Change in reported value | +2.3% |
| New positions | 1 |
| Exited positions | 7 |
| Position turnover | 20.5% |
| Top-10 concentration | 81.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.6B |
|
Q1 2026 13F
Filed May 15, 2026
|
26 | $1.8B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
27 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
29 | $1.8B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
32 | $1.3B |
|
Q1 2025 13F
Filed May 14, 2025
|
37 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
41 | $1.8B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
42 | $1.8B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
41 | $1.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
44 | $1.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
44 | $1.5B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
46 | $1.3B |
|
Q2 2023 13F
Filed Aug 11, 2023
|
44 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
53 | $1.4B |
|
Q4 2022 13F
Filed Feb 10, 2023
|
57 | $1.8B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
57 | $2.0B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
57 | $1.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
57 | $3.5B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
58 | $4.9B |
|
Q3 2021 13F
Filed Nov 12, 2021
|
63 | $8.4B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ACLX ARCELLX INC | $246.6M | 18.56% |
| 2 | VRNA VERONA PHARMA PLC | $214.0M | 16.11% |
| 3 | RYTM RHYTHM PHARMACEUTICALS INC | $183.9M | 13.84% |
| 4 | COUR COURSERA INC | $112.7M | 8.49% |
| 5 | CRSP CRISPR THERAPEUTICS AG | $77.2M | 5.81% |
| 6 | TRVI TREVI THERAPEUTICS INC | $72.3M | 5.44% |
| 7 | SVRA SAVARA INC | $55.8M | 4.2% |
| 8 | ORIC ORIC PHARMACEUTICALS INC | $41.8M | 3.15% |
| 9 | MBX MBX BIOSCIENCES INC | $41.2M | 3.1% |
| 10 | GLUE MONTE ROSA THERAPEUTICS INC | $34.7M | 2.61% |
| 11 | AUPH AURINIA PHARMACEUTICALS INC | $33.6M | 2.53% |
| 12 | CELC CELCUITY INC | $30.6M | 2.31% |
| 13 | ZBIO ZENAS BIOPHARMA INC | $26.5M | 1.99% |
| 14 | GOSS GOSSAMER BIO INC | $22.3M | 1.68% |
| 15 | NEUE NEUEHEALTH INC | $18.8M | 1.42% |
| 16 | PHAT PHATHOM PHARMACEUTICALS INC | $18.8M | 1.42% |
| 17 | KRRO KORRO BIO INC | $13.6M | 1.03% |
| 18 | CSBR CHAMPIONS ONCOLOGY INC | $12.6M | 0.95% |
| 19 | CVRX CVRX INC | $11.9M | 0.9% |
| 20 | BDTX BLACK DIAMOND THERAPEUTICS I | $11.0M | 0.83% |
Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.